Status:
COMPLETED
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epi...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
- Initiating Avastin in combination with chemotherapy
Exclusion
- Contraindications, warnings and precautions for use as specified in the Avastin Summary of Product Characteristics
Key Trial Info
Start Date :
May 10 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01863693
Start Date
May 10 2013
End Date
June 15 2018
Last Update
September 17 2018
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal United Hospital; Oncology Department
Bath, United Kingdom, BA1 3NG
2
City Hospital
Birmingham, United Kingdom, B18 7QH
3
Bradford Royal Infirmary; Oncology Department
Bradford, United Kingdom, BD9 6RJ
4
Bristol Haematology and Oncology Centre
Bristol, United Kingdom, BS2 8ED